NASDAQ:CDTX
Cidara Therapeutics Stock News
$0.92
+0.0779 (+9.25%)
At Close: Mar 28, 2024
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
08:00am, Monday, 17'th Oct 2022
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
12:00pm, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
08:05pm, Tuesday, 20'th Sep 2022 GlobeNewswire Inc.
Assigned PDUFA target action date of March 22, 2023 Assigned PDUFA target action date of March 22, 2023
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
12:00pm, Tuesday, 13'th Sep 2022 GlobeNewswire Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
12:00pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patie
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
08:00am, Tuesday, 06'th Sep 2022
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
11:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
09:16pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
09:04pm, Tuesday, 09'th Aug 2022
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
02:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
07:36pm, Thursday, 12'th May 2022 Benzinga
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.
Cidara confirmed tha
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
03:47pm, Thursday, 12'th May 2022
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed tha